Predictors of diabetes in heart failure Predictors of Development of Diabetes in Patients with Chronic Heart Failure in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program
نویسندگان
چکیده
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK AstaZeneca R&D, Mölndal, Sweden Department of Medicine, Karolinska University Hospital, Solna, Stockholm, Sweden AstraZeneca LP, Wilmington, DE, USA Duke University Medical Center, Durham, NC, USA HGM-McMaster Clinic, Hamilton, Ontario, Canada Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden Brigham & Women’s Hospital, Boston, MA, USA Department of Medicine and the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
منابع مشابه
Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
OBJECTIVE The purpose of this study was to identify predictors of incident diabetes during follow-up of nondiabetic patients with chronic heart failure (CHF) in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. RESEARCH DESIGN AND METHODS A total of 1,620 nondiabetic patients had full baseline datasets. We compared baseline demographic, medic...
متن کاملCandesartan prevented development of diabetes mellitus in heart failure.
M e t h o d s Design: Prespecified secondary analysis of 3 randomized, placebo-controlled trials (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity Program [CHARM]). Allocation: {Concealed}†.* Blinding: Blinded {clinicians, patients, data collectors, outcome assessors, monitoring committee, manuscript writers, and data analysts}†.* Follow-up period: Median 3.1 yea...
متن کاملImpact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
AIMS To determine whether the risk of adverse cardiovascular (CV) outcomes associated with diabetes differs in patients with low and preserved ejection fraction (EF) heart failure (HF). METHODS AND RESULTS We analysed outcomes in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme which randomized 7599 patients with symptomatic HF and a broad ...
متن کاملEffect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
BACKGROUND Patients with heart failure are at increased risk of sudden death and death attributed to progressive pump failure. We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. METHODS AND RESULTS The CHARM program consisted of 3 component trials that en...
متن کاملEvaluation of Serum Ferritin Levels and its Relation with Severity and Duration of Hospitalization in Heart Failure Patients Admitted in Ganjavian Hospital, Ahvaz, Iran
Background: Cardiovascular diseases are one of the most common chronic illnesses. Despite the advancement in the management of heart failure, it still remains as one of the most important causes of mortality and morbidity. Anemia is a common finding in heart failure patients and decreases both life quality and bodily function in this group of patients. It is also related with high mortality and...
متن کامل